**Abstract**

**Objective:** This study is to evaluate the efficacy, functional improvements, and insight improvements in schizophrenic patients with long-acting injectable paliperidone palmitate (PP) treatment.

**Method:** This is a 12-month, open-label, study from Taiwan, included 13 schizophrenic patients, between 17 and 72 years of age. Treatment response was assessed by Positive and Negative Syndrome Scale (PANSS) every month. Patient functioning and insight improvements were assessed via the Personal and Social Performance (PSP) scale and Schedule of Assessment of Insight (SAI--E) every month respectively. Patient were given proper dose (either 150 or 100mg) of paliperidone palmitate in 3\~6 weeks by physician's judgment.

**Results:** Mean maintenance dosage of paliperidone palmitate is 126.67 mg.Only one patient in this study had been hospitalized. There are improvements in mean PANSS score from 66.5 to 62.0, and SAI-E score from 14.6 to 18.01, but slightly decrease in PSP score from 72.5 to 63.5.

**Conclusion:** Paliperidone palmitate is generally tolerable and efficacious in schizophrenic outpatients for the treatment of schizophrenia with significant improvements in psychotic symptoms, and insight. Paliperidone palmitate has a great help in relapse prevention.
